DelveInsight has launched a new report on “Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Biliary Tract Cancers (BTCs) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Biliary Tract Cancers (BTCs), historical and forecasted epidemiology as well as the Biliary Tract Cancers (BTCs) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
Scope of the report:
Key companies Covered:
Biliary Tract Cancer (BTC), also known as Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation.
The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder.
Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis.
It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based upon differences in their tumor biology and management.
According to the ICD 10 classification of the disease, CCA is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) (includes malignant neoplasm of biliary tract whose point of origin cannot be classified to any one of the categories); or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9).
Whole genome sequencing performed by the International Cancer Genome Consortium revealed distinct mutations that affect prognosis. Broadly, BTCs have clusters of mutations in known oncogenes (KRAS, p53, ERBB2/HER2/NEU) and tumor suppressor genes (SMAD-4, BCL-2, p16, and p53).
Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy.
Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Biliary Tract Cancers (BTCs)
3. Competitive Intelligence Analysis for Biliary Tract Cancers (BTCs)
4. Biliary Tract Cancers (BTCs): Market Overview at a Glance
4.1. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2017
4.2. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2030
5. Biliary Tract Cancers (BTCs): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Biliary Tract Cancers (BTCs) Treatment and Management
8.2. Biliary Tract Cancers (BTCs) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Biliary Tract Cancers (BTCs): Seven Major Market Analysis
13.1. Key Findings
13.2. Biliary Tract Cancers (BTCs) Market Size in 7MM
13.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Biliary Tract Cancers (BTCs) Total Market Size in the United States
15.1.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Biliary Tract Cancers (BTCs) Total Market Size in Germany
15.3.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Biliary Tract Cancers (BTCs) Total Market Size in France
15.4.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Biliary Tract Cancers (BTCs) Total Market Size in Italy
15.5.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Biliary Tract Cancers (BTCs) Total Market Size in Spain
15.6.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Biliary Tract Cancers (BTCs) Total Market Size in the United Kingdom
15.7.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Biliary Tract Cancers (BTCs) Total Market Size in Japan
15.8.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Biliary Tract Cancers (BTCs)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for detailed TOC: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market